Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II FOLFOX plus bevacizumab, cetuximab, and imatinib in untreated advanced colorectal cancer
2006-001779-39Phase 2Active
- Sponsor
- IRCCS Ospedale Policlinico San Martino
- Start
- Mar 2007
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, fluorouracil, levoleucovorin, bevacizumab, cetuximab and 1 more in colorectal cancer (CRC), sponsored by IRCCS Ospedale Policlinico San Martino. Primary endpoints: Sustained no evidence of disease rate and Severe toxicity rate. Started Mar 2007; status: active.
02
Drugs
oxaliplatinfluorouracillevoleucovorinbevacizumabcetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2006-001779-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001779-39.